US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

43.27

-1.6400-3.65%

Post-market: 43.00-0.2669-0.62%19:56 EDT

Volume:1.73M

Turnover:74.54M

Market Cap:5.81B

PE:-12.43

High:44.46

Open:44.46

Low:41.25

Close:44.91

52wk High:49.70

52wk Low:8.70

Shares:134.37M

Float Shares:131.11M

Volume Ratio:0.95

T/O Rate:1.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4823

EPS(LYR):-2.0600

ROE:-64.09%

ROA:-20.64%

PB:6.33

PE(LYR):-21.00

Loading ...

Overview Company News Filings

Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs

Definium Therapeutics says first patient dosed in Ascend study

BRIEF-Definium Therapeutics Announces First Patient Dosed In Ascend

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 Odt in Major Depressive Disorder

THOMSON REUTERS

Definium Therapeutics Inc: Topline Data From 12-Week Double-Blind Period Is Anticipated in 2027

THOMSON REUTERS

Definium Therapeutics grants inducement stock options for 255,340 shares to new hires

Definium Therapeutics Is Maintained at Overweight by Piper Sandler

Stock Track | Definium Therapeutics Plummets 5.34% Intraday Following Analyst Price Target Reduction

RBC Capital Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)

Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler

Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX)

Definium Therapeutics releases corporate presentation outlining DT120 ODT Phase 3 program in GAD, MDD

Definium Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Definium Therapeutics Q1 net loss widens on higher R&D costs

Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M

Benzinga Earnings

Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million

BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million

Definium Therapeutics to report first-quarter results in webcast update

Definium Therapeutics Inc : Needham Raises Target Price to $38 From $28

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/DFTX/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":43.27,"timestamp":1787601600000,"preClose":44.91,"halted":0,"volume":1727347,"hourTrading":{"tag":"盘后","latestPrice":43.0031,"preClose":43.27,"latestTime":"19:56 EDT","volume":28156,"amount":1218958.16756,"timestamp":1787615776201,"change":-0.2669,"changeRate":-0.006168,"amplitude":0.02434},"delay":0,"changeRate":-0.036517479403250806,"floatShares":131114280,"shares":134366950,"eps":-3.482311,"marketStatus":"Closed","change":-1.64,"latestTime":"08-24 16:00:00 EDT","open":44.46,"high":44.46,"low":41.25,"amount":74544367.99727,"amplitude":0.071476,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":44.91,"preHourTrading":{"tag":"盘前","latestPrice":44.53,"preClose":44.91,"latestTime":"09:29 EDT","volume":2695,"amount":120581.846,"timestamp":1787578170124,"change":-0.38,"changeRate":-0.008461,"amplitude":0.024271},"postHourTrading":{"tag":"盘后","latestPrice":43.0031,"preClose":43.27,"latestTime":"19:56 EDT","volume":28156,"amount":1218958.16756,"timestamp":1787615776201,"change":-0.2669,"changeRate":-0.006168,"amplitude":0.02434},"volumeRatio":0.954071,"optionData":{"bulkOrders":[{"symbol":"DFTX","call":true,"expireDate":1792123200000,"strike":"45.0","timestamp":1787579284670,"price":4.6,"volume":2000,"amount":920000,"type":"-"}]},"impliedVol":0.8534,"impliedVolPercentile":0.351},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":131114280,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":0.954071,"shares":134366950,"dividePrice":0,"high":44.46,"amplitude":0.071476,"preClose":44.91,"low":41.25,"week52Low":8.7,"pbRate":"6.33","week52High":49.7,"institutionHeld":0,"latestPrice":43.27,"eps":-3.482311,"divideRate":0,"volume":1727347,"delay":0,"ttmEps":-3.482311,"open":44.46,"prevYearClose":13.39,"prevWeekClose":44.91,"prevMonthClose":43.52,"prevQuarterClose":47.04,"fiveDayClose":45.26,"twentyDayClose":42.65,"sixtyDayClose":23.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787025600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-08-21","current":-12.152849,"percent":0.221477,"low":-27.074722,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"high":-8.802064,"avg":-13.793358,"sd":5.619462,"marketCap":6100259530},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530}],"updateTime":1787582368394},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635090783","title":"Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635090783","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635090783?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:35","pubTimestamp":1778668536,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DFTX stock, giving a Buy rating today. Patrick Trucchio has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-with-unchanged-70-price-target-on-robust-late-stage-dt120-pipeline-and-de-risked-phase-3-programs-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-with-unchanged-70-price-target-on-robust-late-stage-dt120-pipeline-and-de-risked-phase-3-programs-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634111902","title":"Definium Therapeutics says first patient dosed in Ascend study","url":"https://stock-news.laohu8.com/highlight/detail?id=2634111902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634111902?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:39","pubTimestamp":1778589593,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluating DT120 ODT for the treat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-says-first-patient-dosed-in-ascend-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-says-first-patient-dosed-in-ascend-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634145218","title":"BRIEF-Definium Therapeutics Announces First Patient Dosed In Ascend","url":"https://stock-news.laohu8.com/highlight/detail?id=2634145218","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634145218?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583658,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Announces First Patient Dosed In AscendMay 12 (Reuters) - Definium Therapeutics Inc DFTX.O:DEFINIUM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ASCEND, THE SECOND PHASE 3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634221890","title":"Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 Odt in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2634221890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634221890?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218985","title":"Definium Therapeutics Inc: Topline Data From 12-Week Double-Blind Period Is Anticipated in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218985?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634510232","title":"Definium Therapeutics grants inducement stock options for 255,340 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2634510232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634510232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529679,"startTime":"0","endTime":"0","summary":"Definium Therapeutics issued inducement stock options covering 255,340 common shares to five newly hired non-executive employees, with grant dates of April 27, May 4, May 11, 2026.Exercise price set at closing share price on each grant date.Vesting scheduled over four years, with 25% vesting on first anniversary of grant date, then remaining 75% vesting in substantially equal monthly installments over next three years, subject to continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8P0Dbr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450206","title":"Definium Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450206","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633450206?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:15","pubTimestamp":1778253300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 11:15 ET (15:15 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105677630","title":"Stock Track | Definium Therapeutics Plummets 5.34% Intraday Following Analyst Price Target Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=1105677630","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105677630?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:35","pubTimestamp":1778247358,"startTime":"0","endTime":"0","summary":"Definium Therapeutics' stock plummeted 5.34% during intraday trading on Friday.The decline follows Piper Sandler analyst David Amsellem lowering the firm's price target on Definium Therapeutics to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633595534","title":"RBC Capital Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633595534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633595534?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:41","pubTimestamp":1778244066,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Definium Therapeutics, with a price target of $36.00. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633257458","title":"Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633257458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633257458?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:19","pubTimestamp":1778239157,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem lowered the firm’s price target on Definium Therapeutics (DFTX) to $48 from $49 and keeps an Overweight rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-lowered-to-48-from-49-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-lowered-to-48-from-49-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633175436","title":"Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633175436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633175436?lang=en_us&edition=fundamental","pubTime":"2026-05-08 16:51","pubTimestamp":1778230270,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX). A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alcon-alc-argenx-se-argx-and-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alcon-alc-argenx-se-argx-and-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","IE00B2B36J28.USD","IE0034235188.USD","IE00BJT1NW94.SGD","BK4139","IE0009355771.USD","LU0128526141.USD","BK4534","IE00BJJMRZ35.SGD","LU1983260115.SGD","BK4581","XBI","HCSG","LU2265009873.SGD","IE0002141913.USD","BK4588","LABU","IE00BFTCPJ56.SGD","BK4007","BK4198","BK4137","LU0109394709.USD","IE00B4R5TH58.HKD","ALC","BK4585","LU1804176565.USD","DFTX","XLV","LU0889565916.HKD","LU2324357040.USD","LU0320765992.SGD","LU0029874061.USD","ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633105303","title":"Definium Therapeutics releases corporate presentation outlining DT120 ODT Phase 3 program in GAD, MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2633105303","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633105303?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:46","pubTimestamp":1778193961,"startTime":"0","endTime":"0","summary":"Definium outlined late-stage plans for DT120 ODT, its lead program, with five Phase 3 studies across generalized anxiety disorder and major depressive disorder.Three Phase 3 readouts are anticipated in 2026, framed as key catalysts for potential commercial opportunities in GAD and MDD.Cash, cash equivalents, and investments totaled USD 373.4 million as of March 31, 2026, with cash runway expected to extend into 2028.Phase 2b data highlighted a single 100 g dose with a 21.9-point HAM-A improvement at Week 12, a 7.7-point placebo-adjusted difference, and 48% remission at Week 12.Pipeline also includes DT402, an R(-)-MDMA program in development for autism spectrum disorder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeut","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLsffrC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177976","title":"Definium Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633177976?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:01","pubTimestamp":1778187702,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryDefinium Therapeutics Inc DFTX.OQ reported a quarterly adjusted loss of 71 cents per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K3AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633949179","title":"Definium Therapeutics Q1 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633949179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633949179?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:11","pubTimestamp":1778184709,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Q1 net loss widens on higher R&D costsOverviewUS biopharma firm posted wider Q1 net loss as R&D and admin expenses increasedCompany ended Q1 with $373.4 mln in cash, seen funding","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K1HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633396179","title":"Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633396179","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633396179?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:09","pubTimestamp":1778184590,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.48) by 47.92 percent. This is a 102.86 percent decrease over losses of $(0.35) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52388273/definium-therapeutics-q1-eps-0-71-misses-0-48-estimate-cash-and-equivalents-of-373-4m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176393","title":"Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176393?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:02","pubTimestamp":1778184153,"startTime":"0","endTime":"0","summary":"Definium Therapeutics posted a net loss of USD 77.1 million, widening from USD 23.3 million a year earlier; loss per share deepened to USD 0.71 from USD 0.27.Operating loss widened to USD 59.2 million from USD 32.2 million as R&D expenses climbed to USD 41.5 million from USD 23.4 million.Cash, cash equivalents, and investments fell to USD 373.4 million from USD 411.6 million at Dec. 31, 2025; cash runway expected to extend into 2028.Enrollment completed for Phase 3 Emerge in MDD and Phase 3 Voyage in GAD, with topline data expected in late 2Q 2026 and early 3Q 2026.Panorama GAD target enrollment updated to 200 with screening closed, pushing topline data to late 3Q 2026; Phase 3 PTSD study Haven planned for 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9NBlDx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633864176","title":"BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633864176","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633864176?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184105,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million\n\n\nMay 07 (Reuters) - Definium Therapeutics Inc Q1 operating expenses USD 59.22 million.\n\nQ1 EPS USD -0.71\nQ1 basic EPS USD -0.71\nQ1 income from operations USD -59.22 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXB42F30:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632766536","title":"Definium Therapeutics to report first-quarter results in webcast update","url":"https://stock-news.laohu8.com/highlight/detail?id=2632766536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632766536?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:02","pubTimestamp":1777579354,"startTime":"0","endTime":"0","summary":"Definium Therapeutics will host live webcast May 7, 2026 at 4:30 p.m. EDT to report first-quarter 2026 financial results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbkzGLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631935635","title":"Definium Therapeutics Inc : Needham Raises Target Price to $38 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2631935635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631935635?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:04","pubTimestamp":1777547091,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631500039","title":"U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta","url":"https://stock-news.laohu8.com/highlight/detail?id=2631500039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631500039?lang=en_us&edition=fundamental","pubTime":"2026-04-30 15:23","pubTimestamp":1777533789,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta April 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alphabet, Amazon a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nL4N41D0U8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APEI","AMR","CMG","AMZN","BEG","CHEF","AMZY","CEG","CSGP","GOOP","AMP","AVT","AVY","BRO","BG","ASH","APH","GOOW","CELH","DFTX","CHRW","GOOY","USAW.SI","GOU","CAKE","AMZZ","CEGX","ALGN","AMZD","GOOG","BIIB","ABG","CNK","CRS","DAN","GOOGL","EAT","APPN","CTSH","CBZ","AFL","CVNA","BE","BHE","ADP","GOOX","CCB","BLKB","ABBV","AMZP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}